Thyroid-associated ophthalmopathy: emergence of teprotumumab as a promising medical therapy
Publication date: Available online 31 January 2020Source: Best Practice &Research Clinical Endocrinology &MetabolismAuthor(s): Terry J. SmithAbstractThyroid-associated ophthalmopathy (TAO) remains a vexing autoimmune component of Graves’ disease that can diminish the quality of life as a consequence of its impact on visual function, physical appearance and emotional well-being. Because of its relative rarity and variable presentation, the development of highly effective and well-tolerated medical therapies for TAO has been slow relative to other autoimmune diseases. Contributing to the barriers of greater insight into TAO has been the historical absence of high-fidelity preclinical animal models. Despite these challenges, several agents, most developed for other diseases, have found their way into consideration for use in active TAO through repurposing from their original purposes. Among these, teprotumumab is a fully human monoclonal antibody that acts as a β-arrestin agonist of the insulin-like growth factor I receptor. It has shown remarkable effectiveness in moderate to severe, active TAO in two completed multicenter, double masked, and placebo controlled clinical trials. The drug exhibits a favorable safety profile. Should teprotumumab become approved by the U.S. F.D.A, it may rapidly become the first line therapy for this disfiguring and potentially blinding condition.
A group of moderately ill people were given hydroxychloroquine, which appeared to ease their symptoms quickly, but more research is needed.
CONCLUSION: Our results indicated that MSC-secretome had DPP-IV/CD26 and APN/CD13 activity. The DPP-IV/CD26 activity was decreased following stimulation of MSCs by toll-like receptor 4 agonist. Further studies are needed to reveal the possible contribution of DPP-IV/CD26 and APN/CD13 in the anti-inflammatory functions of MSC-CM. PMID: 32224540 [PubMed - in process]
Conclusions: IDA significantly increases autoimmune disease risk, particularly in female patients and patients with certain comorbidities. Clinicians should conduct further clinical evaluations and laboratory tests of autoimmune disease in patients with IDA.Plain Language Summary: Little is known about the relationship between iron deficiency and autoimmune disease. By using a national-level database in Taiwan, we noted a meaningful association between iron deficiency anemia (IDA) and later autoimmune disease development. Our study extends the known disease range and recommends that physicians be alert for the occurrence o...
A local biotech is rethinking how to treat autoimmune diseases. It's raised $80 million to do it.
The objective of any FP intervention is to minimize or eliminate primary disease burden and to ensure maintaining or preserving reproductive health. Fertility potential can be affected by cancer therapy and numerous other factors, including advancing age, metabolic conditions, autoimmune diseases, specific surgical interventions, and sex affirmation procedures.
Autoimmune limbic encephalitis is part of CASPR 2 antibody-associated disease. A man with this rare disorder and a very high antibody titre had a unique history of laboratory exposure to the antigen. Together with earlier observations this case calls for caution in laboratory handling of nerve tissue.
There has been greater recognition of allergy and autoimmune disease in pediatric solid organ transplantation, however, their relationship with pediatric heart transplant is unclear. The purpose of this study was to explore post heart transplant immune dysregulation.
This study aimed to evaluate the long-term effects of the first-line immunotherapies on relapse and disability, and identify the prognostic predictors in NMOSD.MethodsIn this prospective cohort study, we enrolled patients with NMOSD from Southwest China and performed a long-term follow-up. We compared no immunotherapies (NIT) versus treatment of mycophenolate mofetil (MMF), azathioprine (AZA), or only corticosteroid (CS). Cox proportional-hazards model was used to explore the prognostic predictors in NMOSD.ResultsUltimately, 281 patients were enrolled during 2009 to 2017. The proportions of relapse, motor disability, and m...
AbstractBy the discovery of an antibody to aquaporin 4 (AQP4), the clinical and radiological findings of neuromyelitis optica (NMO) such as diffuse cerebral or longitudinally extended spinal cord lesions had been clarified as distinct features from multiple sclerosis (MS). Pathological studies in NMO demonstrated loss of immunoreactivity to AQP4 and glial fibrillary acidic protein but a relative preservation of myelin basic protein, especially at the lesions with perivascular deposition of immunoglobulins and complements, suggesting autoimmune disease against astrocytes. In recent years, the antibody against myelin oligode...